What is LH and FSH?
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are gonadotropin hormones of the hypothalamic-pituitary-gonadal axis. This page summarises their identities, receptor family, and the research models in whi
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are gonadotropins — glycoprotein hormones of the anterior pituitary. LH is also written as lutropin; FSH is also written as follitropin. Both are heterodimeric proteins: each consists of a common alpha subunit and a hormone-specific beta subunit, and both act through G-protein-coupled receptors of the glycoprotein hormone receptor family. The evidence block for this page does not supply sequence, formula, or molecular weight values for either hormone, so those identifiers are not stated here.
The work summarised below centres on the hypothalamic-pituitary-gonadal (HPG) axis, in which gonadotropin-releasing hormone (GnRH) drives pulsatile release of LH and FSH, and in which LH and FSH in turn support sex steroid production and gonadal function [3].
Research Studies
Follitropin alfa/lutropin alfa and LH/FSH deficiency in Japanese participants undergoing ART
A registered clinical study (HINATA) was designed to assess the efficacy and safety of follitropin alfa/lutropin alfa versus human menopausal gonadotropin (hMG) in Japanese participants with LH and FSH deficiency undergoing assisted reproductive technology (ART) [1]. The study duration was approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A [1]. This is a trial record; it reports the design and population, not an outcome.
Clomiphene and enclomiphene citrate and gonadotropin endpoints in male hypogonadism
A systematic review and meta-analysis of randomised controlled trials evaluated selective estrogen receptor modulators (SERMs) — specifically clomiphene and enclomiphene — in men with functional hypogonadism [2]. The primary endpoints were total testosterone (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) [2]. Comparators were placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), and the search covered PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov up to July 2024 [2]. Weighted mean differences (MDs) and risk ratios (RRs) were calculated for continuous and binary endpoints respectively [2]. The population in which these endpoints were assessed was men with functional hypogonadism [2].
GLP-1 agonist and neuro-reproductive function in obese adolescent females with PCOS
A registered clinical study examined the effects of a glucagon-like peptide-1 (GLP-1) agonist on neuro-reproductive function in obese adolescent females with polycystic ovary syndrome (PCOS) [3]. The background given for that study states that normal puberty onset and progression depend on a normal HPG axis, which is affected by whole-body metabolism, and that GnRH and the gonadotropins LH and FSH are released in a pulsatile manner for appropriate sex steroid production and gonadal function [3]. The same background states that proper pulsatility in the GnRH system is disrupted by a significant change in energy balance such as in obesity, and that PCOS is the most common neuroendocrine disorder in this context [3]. The population in which these observations were framed was obese adolescent females with PCOS [3].
Comparison of study populations and gonadotropin-related endpoints
| Study | Population | Intervention or exposure | Gonadotropin-related endpoint |
|---|---|---|---|
| HINATA [1] | Japanese participants with LH and FSH deficiency undergoing ART | Follitropin alfa/lutropin alfa versus hMG | Efficacy and safety (design-level) |
| SERM meta-analysis [2] | Men with functional hypogonadism | Clomiphene or enclomiphene versus placebo, T gel, or hCG | TT, FSH, LH |
| GLP-1 study [3] | Obese adolescent females with PCOS | GLP-1 agonist | Neuro-reproductive function (design-level) |
Receptor and pathway context
LH and FSH act within the HPG axis, where GnRH and the gonadotropins are released in a pulsatile manner to support sex steroid production and gonadal function [3]. The evidence block does not provide receptor-binding affinities, signalling cascades, or tissue-distribution data beyond this axis-level description, so no further mechanistic claims are made here.
Where the evidence is animal-only or in vitro
The evidence block for this page contains no animal-only or in vitro studies. All three entries are either registered clinical studies or a systematic review and meta-analysis of randomised controlled trials in human populations [1][2][3]. No animal or cell-culture findings are reported in the supplied evidence, and none are asserted.
What the evidence does not establish
The supplied evidence does not provide sequence data, molecular weight, half-life, dose-response relationships, or comparative potency between LH and FSH. It also does not report efficacy outcomes from the HINATA or GLP-1 study records, which are design descriptions [1][3]. The meta-analysis reports that weighted mean differences and risk ratios were calculated for its endpoints, but the numeric results are not included in the evidence block [2].
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) — ClinicalTrials.gov
- [2] Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. — Europe PMC
- [3] Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) — ClinicalTrials.gov